Achillion Pharmaceuticals, Inc. has begun dosing study participants with ACH-3422, Achillion’s proprietary uridine-analog nucleotide inhibitor, in a Phase 1 clinical trial. ACH-3422 is being developed for use in combination regimens to treat chronic hepatitis C viral infection (HCV).

Achillion also announced the initiation of dosing in a Phase 2 pilot study evaluating ACH-3102, Achillion’s second-generation NS5A inhibitor, in combination with sofosbuvir for eight and potentially six weeks of treatment for patients with chronic genotype 1 treatment-naïve HCV.

— UPCOMING EVENTS —

5/12 5:00 pm – 6:30 pm in New Haven
BioScienceClubhouseCT presents ‘SystaMedic: A Novel Cause-Effect Analysis Platform for Predicting Probability of R&D Program Success’  … more

6/5 4:00 pm – 6:00 pm in New Haven
BioHaven panel discussion and CURE Annual Meeting. Watch for details!